Myriad Pushes For Isolated DNA Patents In Fed. Circ.

Law360, New York (April 4, 2011, 6:05 PM EDT) -- Myriad Genetics Inc. tried to persuade the Federal Circuit on Monday that seven of its patents for isolated human genes were not invalid for merely being products of nature, as a lower court ruled.

A three-judge panel of the U.S. Court of Appeals for the Federal Circuit heard the Association for Molecular Pathology argue, in response, that the seven isolated gene patents at issue were not materially different from their original form in the human body.

Judge Robert W. Sweet's March ruling in the U.S. District...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.